Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Kidney International

• Publication date

  2001-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/J.1523-1755.2001.0590051899.XPMID 11318962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progression and potential regression of glomerulosclerosis.

  2001cited by this paper
• The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis.

  2000cited by this paper
• Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.

  2000cited by this paper
• Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation.

  2000cited by this paper
• Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.

  2000cited by this paper
• Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

  2000cited by this paper
• Regulation of mesangial cell proliferation.

  1999cited by this paper
• PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease

  1999cited by this paper
• Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

  1999cited by this paper
• PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.

  1999cited by this paper
• Ligand structure influences autologous downregulation of estrogen receptor-alpha messenger RNA.

  1999cited by this paper
• Mesangial Matrix Modulation and Glomerulosclerosis

  1999cited by this paper
• A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.

  1999cited by this paper
• Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.

  1999cited by this paper
• Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.

  1999cited by this paper
• HYPERTENSION AND INSULIN RESISTANCE: ROLE OF PEROXISOME PROLIFERATOR‐ACTIVATED RECEPTOR γ

  1999cited by this paper
• Cell cycle regulatory proteins in glomerular disease.

  1999cited by this paper
• Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis.

  1999cited by this paper
• Down-regulation of transforming growth factor-beta receptors: cooperativity between the types I, II, and III receptors and modulation at the cell surface.

  1999cited by this paper
• Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice.

  1999cited by this paper
• A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.

  1999cited by this paper
• The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure.

  1999cited by this paper
• Cell Cycle Regulatory Proteins in Glomerular Disease

  1999cited by this paper
• Expression of Peroxisome Proferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death

  1999cited by this paper
• The lack of a functional p21WAF1/CIP1 gene ameliorates progression to chronic renal failure

  1999cited by this paper
• Expression of p21Cip1/Waf1/Sdi1 and p27Kip1Cyclin-Dependent Kinase Inhibitors During Human Hematopoiesis

  1999cited by this paper
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.

  1998cited by this paper
• Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ

  1998cited by this paper
• Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma.

  1998cited by this paper
• Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Inhibiting CDK inhibitors: new lessons from DNA tumor viruses.

  1998cited by this paper
• Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.

  1998cited by this paper
• PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.

  1998cited by this paper
• Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats

  1998cited by this paper
• PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL

  1998cited by this paper
• Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.

  1997cited by this paper
• Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans.

  1997cited by this paper
• Endothelial Function, Fibrinolysis, and Angiotensin‐Converting Enzyme Inhibition

  1997cited by this paper
• Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs*

  1997cited by this paper
• Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.

  1997cited by this paper
• Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo.

  1997cited by this paper
• Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.

  1997cited by this paper
• New functional activities for the p21 family of CDK inhibitors.

  1997cited by this paper
• Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone.

  1996cited by this paper
• Identification of a Peroxisome Proliferator-responsive Element Upstream of the Human Peroxisomal Fatty Acyl Coenzyme A Oxidase Gene (*)

  1996cited by this paper
• Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis.

  1996cited by this paper
• The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones

  1996cited by this paper
• Inhibition of oxidation of low density lipoprotein by troglitazone.

  1996cited by this paper
• Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

  1996cited by this paper
• Adipocyte differentiation: a transcriptional regulatory cascade.

  1996cited by this paper
• The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

  1996cited by this paper
• Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

  1996cited by this paper
• An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*)

  1995cited by this paper
• 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

  1995cited by this paper
• 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ

  1995cited by this paper
• Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*)

  1995cited by this paper
• A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

  1995cited by this paper
• TGF-beta: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention.

  1995cited by this paper
• The nuclear receptor superfamily: the second decade.

  1995cited by this paper
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• Pioglitazone Increases Insulin Sensitivity, Reduces Blood Glucose, Insulin, and Lipid Levels, and Lowers Blood Pressure, in Obese, Insulin-Resistant Rhesus Monkeys

  1994cited by this paper
• Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.

  1994cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.

  1993cited by this paper
• Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E.

  1993cited by this paper
• Role of lipids in the progression of renal disease in chronic renal failure: evidence from animal studies and pathogenesis.

  1993cited by this paper
• Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats.

  1993cited by this paper
• Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response.

  1992cited by this paper
• Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure.

  1992cited by this paper
• Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.

  1992cited by this paper
• Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation.

  1992cited by this paper
• Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions.

  1991cited by this paper
• Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation. Evidence for involvement of macrophages and lipids.

  1991cited by this paper
• Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM

  1991cited by this paper
• Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1

  1990cited by this paper
• The mesangium in anti-Thy-1 nephritis. Influx of macrophages, mesangial cell hypercellularity, and macromolecular accumulation.

  1990cited by this paper
• Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis.

  1989cited by this paper
• G1 events and regulation of cell proliferation.

  1989cited by this paper
• Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

  1989cited by this paper
• Banting lecture 1988. Role of insulin resistance in human disease.

  1988cited by this paper
• "Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy.

  1988cited by this paper
• Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats

  1988cited by this paper
• Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus

  1988cited by this paper
• Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis.

  1988cited by this paper
• Role of Insulin Resistance in Human Disease

  1988cited by this paper
• Secretory products of macrophages.

  1987cited by this paper
• Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.

  1986cited by this paper
• Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

  1983cited by this paper

• Polyunsaturated fatty acids in kidney diseases: Navigating the fine line between healing and damage.

  2025cites this paper
• Low-Dose Erythropoietin Amplifies Beneficial Effects of Angiotensin II Blockade on Glomerulosclerosis.

  2023cites this paper
• YY1-induced upregulation of LncRNA-ARAP1-AS2 and ARAP1 promotes diabetic kidney fibrosis via aberrant glycolysis associated with EGFR/PKM2/HIF-1α pathway

  2023cites this paper
• Comparing the Effect of Moringa Aqueous Extract and Selenium Nanoparticles Against Complications of Type 2 Diabetes Mellitus.

  2023cites this paper
• Excessive Activation of Notch Signaling in Macrophages Promote Kidney Inflammation, Fibrosis, and Necroptosis

  2022cites this paper
• Alternatively Spliced Landscape of PPARγ mRNA in Podocytes Is Distinct from Adipose Tissue

  2022influential citation
• Nuclear Receptors and Transcription Factors in Obesity-Related Kidney Disease.

  2021cites this paper
• Drug Therapies Affecting Renal Function: An Overview

  2021cites this paper
• Selective modulator of nuclear receptor PPARγ with reduced adipogenic potential ameliorates experimental nephrotic syndrome

  2021cites this paper
• PPARγ and TGFβ—Major Regulators of Metabolism, Inflammation, and Fibrosis in the Lungs and Kidneys

  2021cites this paper
• Nuclear receptors in podocyte biology and glomerular disease

  2020cites this paper
• Emerging drugs for treatment of focal segmental glomerulosclerosis

  2020cites this paper
• PPARγ and Its Agonists in Chronic Kidney Disease

  2020cites this paper
• Phthalate exposure increased the risk of early renal impairment in Taiwanese without type 2 diabetes mellitus.

  2019cites this paper
• The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3

  2019cites this paper
• Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy.

  2019cites this paper
• WITHDRAWN: Local miscommunications between glomerular cells as potential therapeutic targets for crescentic glomerulonephritides.

  2019cites this paper
• Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy

  2018cites this paper
• Glucose Transporters in Diabetic Kidney Disease—Friends or Foes?

  2018cites this paper
• Urine mitochondrial DNA and diabetic nephropathy-a new frontier.

  2018cites this paper
• Plasticizer Di-(2-Ethylhexyl)Phthalate Induces Epithelial-to-Mesenchymal Transition and Renal Fibrosis In Vitro and In Vivo

  2018cites this paper
• Klotho and PPAR Gamma Activation Mediate the Renoprotective Effect of Losartan in the 5/6 Nephrectomy Model

  2018cites this paper
• Regulation of Prostaglandin Synthesis

  2017cites this paper
• Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice

  2017cites this paper
• Drug Discovery in Tissue Fibrosis

  2017cites this paper
• Sildenafil obviates ischemia-reperfusion injury-induced acute kidney injury through peroxisome proliferator-activated receptor γ agonism in rats.

  2016cites this paper
• Anti-inflammatory effect of combination therapy with rosiglitazone and all- trans retinoic acid on high glucose-induced MCP-1 response in rat mesangial cells

  2016cites this paper
• Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor γ Essential for Resistance to Crescentic GN.

  2016cites this paper
• Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis

  2016cites this paper
• Cancer drug troglitazone stimulates the growth and response of renal cells to hypoxia inducible factors.

  2016cites this paper
• Peroxisome proliferator activating receptor‐&ggr; and the podocyte

  2016cites this paper
• Estrogen attenuates renal IRI through PPAR-γ agonism in rats.

  2016cites this paper
• Inhibitory effects of peroxisome proliferator-activated receptor γ agonists on collagen IV production in podocytes

  2015cites this paper
• Paediatrics, insulin resistance and the kidney

  2015cites this paper
• Peroxisome proliferator-activated receptor γ prevents the production of NOD-like receptor family, pyrin domain containing 3 inflammasome and interleukin 1β in HK-2 renal tubular epithelial cells stimulated by monosodium urate crystals.

  2015cites this paper
• Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate Restores Nrf2 Activity and Ameliorates Crescentic Glomerulonephritis

  2015cites this paper
• TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?

  2015cites this paper
• Mitochondrial dysfunction in the pathophysiology of renal diseases.

  2014cites this paper
• Méthodes pour la prévention et le traitement de la glomérulonéphrite rapidement progressive

  2014cites this paper
• Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat.

  2014cites this paper
• Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney

  2014cites this paper
• Recent advances in our understanding of insulin signalling to the podocyte.

  2014cites this paper
• Explicit role of peroxisome proliferator-activated receptor gamma in gallic acid-mediated protection against ischemia-reperfusion-induced acute kidney injury in rats.

  2014cites this paper
• Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models

  2013cites this paper
• Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss.

  2013cites this paper
• Curcumin Inhibits Transforming Growth Factor-β1-Induced EMT via PPARγ Pathway, Not Smad Pathway in Renal Tubular Epithelial Cells

  2013cites this paper
• Pioglitazone inhibits high glucose-induced synthesis of extracellular matrix by NF-κB and AP-1 pathways in rat peritoneal mesothelial cells.

  2013cites this paper
• Insulin signalling to the kidney in health and disease.

  2013cites this paper
• Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines.

  2013cites this paper
• Die Bedeutung des Sphingolipidstoffwechsels für die Generierung von inflammatorischen und fibrotischen Mediatoren in renalen Mesangiumzellen

  2013cites this paper
• Childhood nephrotic syndrome—current and future therapies

  2012cites this paper
• The role of nuclear receptors in the kidney in obesity and metabolic syndrome

  2012cites this paper
• Diagnostic/Pathogenetic Features, Quantification, and Clinicopathologic Implications

  2012cites this paper
• Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model

  2012cites this paper
• The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes

  2012cites this paper
• An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome.

  2012cites this paper
• Thiazolidinedione‐dependent activation of sphingosine kinase 1 causes an anti‐fibrotic effect in renal mesangial cells

  2012cites this paper
• Inflammation and Fibrosis – Interactions and Impact on the Kidney

  2012cites this paper
• The role of animal models in the understanding and treatment of focal segmental glomerulosclerosis : a review of the literature

  2012cites this paper
• Inhibitory Effects of Rosiglitazone on Lipopolysaccharide-Induced Inflammation in a Murine Model and HK-2 Cells

  2011cites this paper
• Oxidative Stress in Kidney Injury: Peroxisome Proliferator-Activated Receptor-γ Agonists Are in Control

  2011cites this paper
• PPARγ and chronic kidney disease

  2011cites this paper
• Esculetin induced changes in Mmp13 and Bmp6 gene expression and histone H3 modifications attenuate development of glomerulosclerosis in diabetic rats.

  2011cites this paper
• Rosiglitazone Inhibits Transforming Growth Factor-β1 Mediated Fibrogenesis in ADPKD Cyst-Lining Epithelial Cells

  2011cites this paper
• PPAR-γ agonism for cardiovascular and renal protection.

  2011cites this paper
• Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.

  2011cites this paper
• Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease

  2011cites this paper
• Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-γ.

  2011cites this paper
• The green tea polyphenol (-)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis.

  2011cites this paper
• Reduction of proteinuria by pioglitazone in patients with non-diabetic renal disease

  2011cites this paper
• Glomerulonephritis and Cellular Regulation of Prostaglandin Synthesis

  2011cites this paper
• Comparison of Direct Action of Thiazolidinediones and Glucocorticoids on Renal Podocytes: Protection from Injury and Molecular Effects

  2011cites this paper
• Antifibrotic Effects of Pioglitazone at Low Doses on the Diabetic Rat Kidney Are Associated with the Improvement of Markers of Cell Turnover, Tubular and Endothelial Integrity, and Angiogenesis

  2010cites this paper
• Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone.

  2010cites this paper
• Effect of rosiglitazone on cisplatin-induced nephrotoxicity

  2010cites this paper
• Renal PPARγ mRNA expression increases with impairment of renal function in patients with chronic kidney disease

  2010cites this paper
• The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.

  2010cites this paper
• Opposite Action of Peroxisome Proliferator-activated Receptor-γ in Regulating Renal Inflammation

  2010cites this paper
• PPARγ agonists inhibit TGF-β-PKA signaling in glomerulosclerosis

  2010cites this paper
• Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice

  2010cites this paper
• Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease – Future Promise, Present Fears

  2009cites this paper
• Slower decline of renal function after initiation of rosiglitazone in diabetics -- a pilot study.

  2009cites this paper
• Peroxisome proliferator‐activated receptor‐γ abrogates Smad‐dependent collagen stimulation by targeting the p300 transcriptional coactivator

  2009cites this paper
• Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms.

  2009cites this paper
• PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis

  2009cites this paper
• Lipids as targets for novel anti-inflammatory therapies.

  2009cites this paper
• 2 PPAR Research susceptibility to renal damage in a rat renal injury model

  2009cites this paper
• Early Detection and conservative Management of chronic renal failure

  2009cites this paper
• Genetic podocyte lineage reveals progressive podocytopenia with parietal cell hyperplasia in a murine model of cellular/collapsing focal segmental glomerulosclerosis.

  2009cites this paper
• PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β

  2009cites this paper
• Comparative proteome analysis of TGF‐β1‐induced fibrosis processes in normal rat kidney interstitial fibroblast cells in response to ascofuranone

  2009cites this paper
• The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.

  2009cites this paper
• Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation.

  2009cites this paper
• Peroxisome proliferator-activated receptors and renal diseases.

  2009cites this paper
• Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy

  2009cites this paper
• Role of rosiglitazone in lipopolysaccharide‐induced peritonitis: A rat peritoneal dialysis model

  2009cites this paper
• Hyperglycemia Treatment in Patients with Diabetes Mellitus and Chronic Kidney Disease

  2009cites this paper
• Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.

  2009cites this paper
• Protective Actions of PPAR-γ Activation in Renal Endothelium

  2009cites this paper
• PPARs and the kidney in metabolic syndrome.

  2008cites this paper